Table 2.
Univariate survival analysis of various factors in patients with PDAC
| Characteristic | (n) | Median Survival Time | P value |
|---|---|---|---|
| Age | 0.066 | ||
| ≤58 | 72 | 12.6 | |
| >58 | 64 | 12.2 | |
| Gender | 0.09 | ||
| Man | 80 | 10 | |
| Women | 56 | 12.1 | |
| Tumor size | <0.001* | ||
| ≤3cm | 68 | 12.9 | |
| >3cm | 68 | 11.3 | |
| Differentiation | <0.001* | ||
| Poor | 60 | 14.1 | |
| Well and moderate | 76 | 10.4 | |
| Tumor Stage | 0.159 | ||
| Ⅰ,Ⅱ | 80 | 13.1 | |
| Ⅲ,Ⅳ | 56 | 11 | |
| Lymph node metastasis | 0.074 | ||
| NO | 68 | 13.1 | |
| YES | 68 | 11.6 | |
| Distant metastasis | 0.032* | ||
| M0 | 120 | 12.5 | |
| M1 | 16 | 8 | |
| DEK | <0.001* | ||
| Low expression | 60 | 15 | |
| High expression | 76 | 10.5 | |
| CA19-9 | 0.012* | ||
| ≤37 IU/ml | 76 | 14.4 | |
| >37 IU/ml | 60 | 8.7 | |
| DEK and CA19-9 | <0.001* | ||
| Low DEK and CA19-9 ≤37 IU/ml | 40 | 15.9 | |
| High DEK or CA19-9 >37 IU/ml | 60 | 12.5 | |
| High DEK and CA19-9 >37 IU/ml | 36 | 8.2 | |
* P < 0.05